Heidelberg Innovation, Earlybird and Forbion Capital Partners have exited their stakes in Alantos Pharmaceuticals Holding to US-based biotechnology company Amgen. Under the terms of the agreement, Amgen will pay $300m in cash to acquire Alantos.
Deal includes three manufacturing facilities located in Spain, which employ around 140 staff
GP acquired the care home group from Swiss Prime Site and will be the company's sole shareholder
Iris, Idinvest and historical backers invest in the manager of the eponymous social media app
GP uses its Mérieux Participations 3 fund, which held a first close on €200m in 2018